Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in Neurology
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sándor, P. S.
Right arrow Articles by Schoenen, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sándor, P. S.
Right arrow Articles by Schoenen, J.
Related Collections
Right arrow All Clinical trials
Right arrow Clinical trials Randomized controlled (CONSORT agreement)
Right arrow Migraine
NEUROLOGY 2005;64:713-715
© 2005 American Academy of Neurology
Brief Communications

Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial

P. S. Sándor, MD, L. Di Clemente, MD, G. Coppola, MD, U. Saenger, A. Fumal, MD, D. Magis, MD, L. Seidel, MSc, R. M. Agosti, MD and J. Schoenen, MD, PhD

From the Headache and Pain Unit (Drs. Sándor and Agosti, U. Saenger), Neurology Department, University Hospital Zurich; Zurich Hirslanden Headache Center (Dr. Agosti, U. Saenger), Zurich, Switzerland; Department of Neurology (Drs. Schoenen, Di Clemente, Coppola, Fumal, and Magis), CHR Citadelle, Liège; and Department of Biostatistics and Medical Informatics (L. Seidel), CHU Sart Tilman, University of Liège, Liège, Belgium.

Address correspondence and reprint requests to Dr. med. Peter S. Sándor, Headache and Pain Unit, Neurology Department, University Hospital Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland

Riboflavin, which improves energy metabolism similarly to coenzyme Q10 (CoQ10), is effective in migraine prophylaxis. We compared CoQ10 (3 x 100 mg/day) and placebo in 42 migraine patients in a double-blind, randomized, placebo-controlled trial. CoQ10 was superior to placebo for attack-frequency, headache-days and days-with-nausea in the third treatment month and well tolerated; 50%-responder-rate for attack frequency was 14.4% for placebo and 47.6% for CoQ10 (number-needed-to-treat: 3). CoQ10 is efficacious and well tolerated.


Related articles in Neurology:

February 22 Highlights

Neurology 2005 64: 586-587. [Full Text]  



This article has been cited by other articles:


Home page
 Arch. Dis. Child.Home page
T Higashimoto, E E Baldwin, J I Gold, and R G Boles
Reflex sympathetic dystrophy: complex regional pain syndrome type I in children with mitochondrial disease and maternal inheritance
Arch. Dis. Child., May 1, 2008; 93(5): 390 - 397.
[Abstract] [Full Text] [PDF]

Home page
 PNHome page
D W Dodick and S D Silberstein
Migraine prevention
Practical Neurology, November 1, 2007; 7(6): 383 - 393.
[Abstract] [Full Text] [PDF]

Home page
 JAOA: Journal of the American Osteopathic AssociationHome page
A. Vasquez
Interventions Need to Be Consistent With Osteopathic Philosophy
J Am Osteopath Assoc, September 1, 2006; 106(9): 528 - 529.
[Full Text] [PDF]

Home page
 JWatch PsychiatryHome page
Alternative Treatment for Migraines: CoQ10
Journal Watch Psychiatry, April 6, 2005; 2005(406): 5 - 5.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.